Targeting glucose metabolism to develop anticancer treatments and therapeutic patents Y Zhou, Y Guo, KY Tam Expert opinion on therapeutic patents 32 (4), 441-453, 2022 | 20 | 2022 |
The development of small-molecule inhibitors targeting hexokinase 2 W Shan, Y Zhou, KY Tam Drug Discovery Today 27 (9), 2574-2585, 2022 | 19 | 2022 |
Recent developments of human monocarboxylate transporter (hMCT) inhibitors as anticancer agents P Wu, Y Zhou, Y Guo, SL Zhang, KY Tam Drug Discovery Today 26 (3), 836-844, 2021 | 12 | 2021 |
Epigallocatechin gallate circumvents drug‐induced resistance in non‐small‐cell lung cancer by modulating glucose metabolism and AMPK/AKT/MAPK axis Y Zhou, S Huang, Y Guo, M Ran, W Shan, WH Chen, KY Tam Phytotherapy Research 37 (12), 5837-5853, 2023 | 4 | 2023 |
Combined inhibition of pyruvate dehydrogenase kinase 1 and lactate dehydrogenase a induces metabolic and signaling reprogramming and enhances lung adenocarcinoma cell killing Y Zhou, Y Guo, M Ran, W Shan, C Granchi, E Giovannetti, F Minutolo, ... Cancer Letters 577, 216425, 2023 | 4 | 2023 |
Breast tumor‐targeted drug delivery via polymer nanocarriers: Endogenous and exogenous strategies M Zhu, X Wang, Y Zhou, M Li, Y Wang, Y Wang, T Li, SY Song, B Zhang, ... Journal of Applied Polymer Science 140 (31), e54227, 2023 | 4 | 2023 |
Dichloroacetophenone biphenylsulfone ethers as anticancer pyruvate dehydrogenase kinase inhibitors in non-small cell lung cancer models Y Guo, Y Zhou, P Wu, M Ran, N Xu, W Shan, O Sha, KY Tam Chemico-Biological Interactions 378, 110467, 2023 | 4 | 2023 |
Combined inhibition of pyruvate dehydrogenase kinase 1 and hexokinase 2 induces apoptsis in non-small cell lung cancer cell models Y Guo, X Lu, Y Zhou, WH Chen, KY Tam Experimental Cell Research 433 (2), 113830, 2023 | | 2023 |
Cytosolic malic enzyme and glucose‐6‐phosphate dehydrogenase modulate redox balance in NSCLC with acquired drug resistance M Ran, Y Zhou, Y Guo, D Huang, SL Zhang, KY Tam The FEBS Journal 290 (19), 4792-4809, 2023 | | 2023 |